ConvaTec Group PLC (LON:CTEC – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is GBX 306.
A number of equities analysts recently weighed in on CTEC shares. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 300 price objective on shares of ConvaTec Group in a research report on Monday, June 8th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 315 price objective on shares of ConvaTec Group in a research report on Wednesday, April 8th. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 315 price objective on shares of ConvaTec Group in a research report on Wednesday, March 11th. JPMorgan Chase & Co. lowered their price objective on shares of ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating on the stock in a research report on Friday, May 22nd. Finally, Citigroup lowered their price objective on shares of ConvaTec Group from GBX 250 to GBX 230 and set a “neutral” rating on the stock in a research report on Monday, May 18th.
Check Out Our Latest Research Report on ConvaTec Group
Insiders Place Their Bets
ConvaTec Group Stock Performance
Shares of CTEC opened at GBX 206.97 on Friday. The company has a current ratio of 1.53, a quick ratio of 0.96 and a debt-to-equity ratio of 99.96. The firm has a market cap of £4.05 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 0.93 and a beta of 0.76. The company’s 50 day simple moving average is GBX 211.85 and its 200-day simple moving average is GBX 225.62. ConvaTec Group has a 12-month low of GBX 193 and a 12-month high of GBX 294.20.
About ConvaTec Group
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Recommended Stories
- Five stocks we like better than ConvaTec Group
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
